Qiqi Zhang1,2,3,4, Cheng Zu1,2,3,4, Ye Meng1,2,3,4, Yuqi Lyu1,2,3,4, Yongxian Hu1,2,3,4, He Huang1,2,3,4. 1. 1. Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China. 2. 2. Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou 311121, China. 3. 3. Institute of Hematology, Zhejiang University, Hangzhou 310058, China. 4. 4. Zhejiang Provincial Laboratory for Stem Cell and Immunity Therapy, Hangzhou 310058, China.
Abstract
OBJECTIVE: To investigate the risk factors of tumor lysis syndrome (TLS) in relapsed/refractory multiple myeloma (MM) patients undergoing B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy. METHOD: The clinical data of 99 relapsed/refractory MM patients receiving BCMA CAR-T cell therapy in the First Affiliated Hospital, Zhejiang University School of Medicine from July 2018 to December 2021 were collected in this study. Univariate analysis and multivariate logistic regression were performed to evaluate the risk factors of TLS following BCMA CAR-T cell therapy. RESULTS: Among the 99 patients, TLS occurred in 17 cases (17.2%) with an onset time of (8.9±3.0) d after BCMA CAR-T cell therapy. All TLS patients developed TLS-related clinical manifestations, including 17 cases with renal dysfunction, 8 cases with arrhythmia. All TLS patients developed cytokine release syndrome (CRS) with an onset of 1.0 (1.0, 6.5) d after CAR-T cell therapy, and 13 cases developed grade 3-4 CRS. The levels of serum uric acid, serum creatinine and the ratio of cases with grade 3-4 CRS were significantly higher in TLS patients than in non-TLS patients (all P<0.05). Multivariate logistic regression revealed that serum creatinine ( OR=1.015, P<0.01) and severe CRS ( OR=9.371, P<0.01) were independent risk factors of TLS. CONCLUSIONS: Relapsed/refractory MM patients undergoing BCMA CAR-T therapy shows high incidence of TLS, which are related to elevated levels of serum creatinine and severe CRS. TLS can be prevented clinically by reducing serum creatinine and controlling CRS severity.
OBJECTIVE: To investigate the risk factors of tumor lysis syndrome (TLS) in relapsed/refractory multiple myeloma (MM) patients undergoing B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy. METHOD: The clinical data of 99 relapsed/refractory MM patients receiving BCMA CAR-T cell therapy in the First Affiliated Hospital, Zhejiang University School of Medicine from July 2018 to December 2021 were collected in this study. Univariate analysis and multivariate logistic regression were performed to evaluate the risk factors of TLS following BCMA CAR-T cell therapy. RESULTS: Among the 99 patients, TLS occurred in 17 cases (17.2%) with an onset time of (8.9±3.0) d after BCMA CAR-T cell therapy. All TLS patients developed TLS-related clinical manifestations, including 17 cases with renal dysfunction, 8 cases with arrhythmia. All TLS patients developed cytokine release syndrome (CRS) with an onset of 1.0 (1.0, 6.5) d after CAR-T cell therapy, and 13 cases developed grade 3-4 CRS. The levels of serum uric acid, serum creatinine and the ratio of cases with grade 3-4 CRS were significantly higher in TLS patients than in non-TLS patients (all P<0.05). Multivariate logistic regression revealed that serum creatinine ( OR=1.015, P<0.01) and severe CRS ( OR=9.371, P<0.01) were independent risk factors of TLS. CONCLUSIONS: Relapsed/refractory MM patients undergoing BCMA CAR-T therapy shows high incidence of TLS, which are related to elevated levels of serum creatinine and severe CRS. TLS can be prevented clinically by reducing serum creatinine and controlling CRS severity.
Entities:
Keywords:
B cell maturation antigen; Chimeric antigen receptor T cell; Multiple myeloma; Risk factor; Tumor lysis syndrome
Authors: Paul G Richardson; Philippe Moreau; Jacob P Laubach; Michelle E Maglio; Sagar Lonial; Jesus San-Miguel Journal: Pharmacol Res Date: 2016-11-21 Impact factor: 7.658
Authors: Nikhil C Munshi; Larry D Anderson; Nina Shah; Deepu Madduri; Jesús Berdeja; Sagar Lonial; Noopur Raje; Yi Lin; David Siegel; Albert Oriol; Philippe Moreau; Ibrahim Yakoub-Agha; Michel Delforge; Michele Cavo; Hermann Einsele; Hartmut Goldschmidt; Katja Weisel; Alessandro Rambaldi; Donna Reece; Fabio Petrocca; Monica Massaro; Jamie N Connarn; Shari Kaiser; Payal Patel; Liping Huang; Timothy B Campbell; Kristen Hege; Jesús San-Miguel Journal: N Engl J Med Date: 2021-02-25 Impact factor: 91.245
Authors: Sagar Lonial; Brendan M Weiss; Saad Z Usmani; Seema Singhal; Ajai Chari; Nizar J Bahlis; Andrew Belch; Amrita Krishnan; Robert A Vescio; Maria Victoria Mateos; Amitabha Mazumder; Robert Z Orlowski; Heather J Sutherland; Joan Bladé; Emma C Scott; Albert Oriol; Jesus Berdeja; Mecide Gharibo; Don A Stevens; Richard LeBlanc; Michael Sebag; Natalie Callander; Andrzej Jakubowiak; Darrell White; Javier de la Rubia; Paul G Richardson; Steen Lisby; Huaibao Feng; Clarissa M Uhlar; Imran Khan; Tahamtan Ahmadi; Peter M Voorhees Journal: Lancet Date: 2016-01-07 Impact factor: 79.321
Authors: Teru Hideshima; Constantine Mitsiades; Giovanni Tonon; Paul G Richardson; Kenneth C Anderson Journal: Nat Rev Cancer Date: 2007-08 Impact factor: 60.716